effectiveness of Pama-Dadru-Vicharchikahar lepa (1) in Vicharchika (Eczema)

Randomised controlled clinical study to evaluate the efficacy of pama-dadru-vicharchikahar lepa (1) topically in the management of vicharchika(Eczema).

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/06/025982

Enrollment

Registered

2020-06-19

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L239- Allergic contact dermatitis, unspecified cause

Interventions

Intervention1: Pama-Dadru-Vicharchikahar Lepa (1): Pama-Dadru-Vicharchikahar Lepa (1) Local application for twice a day for 6 weeks Control Intervention1: Mometasone Furoate 0.1% ointment: Mometasone

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age group above 16 and below 70 years. 2) patient having classical signs and symptoms of vicharchika, a) Kandu (itching) b) Pidika (eruption) c) Syava varna (blackish discolouration) d) Strava (discharge) e) Ruja (pain) f) Rajyo (marked lining due to thickness of lesion) g) Rukshata(dryness) h) lohit varna (redness of lesion ) 3) Patient willing for clinical trial. 4) Irrespective of gender, occupation, Religion, economical barrier. 5) patients willing to participate. 6) patients who will fulfil criteria and take regular medicines with regular follow up. 7) Patient having controlled thyroid 8) Patient having controlled HTN

Exclusion criteria

Exclusion criteria: 1) Age group below 16 years and above 70 years . 2) Pregnant and lactating mother. 3) Infective origins like a)Kochâ??s b) Hansenâ??s disease 17 7.6 c) Scabies d) Fungal infection /herpes zoster. 4) Drug induced eczema. 5) Immune compromised like HIV,HBV 6) Systemic disorders DM,CVV 7) Diabetic wound 8) Renal diseases like CKD 9) Endocrine disorders will exclude from study to avoid over lapping of symptoms. 10) Psoriasis, Pulmonary tuberculosis.

Design outcomes

Primary

Measure	Time frame
To study the therapeutic effect of Pama-Dadru-Vicharchikaha lepa(1) compare to Mometasone Furoate (0.1%) in the management of vicharchika.Timepoint: 7th 14th 21th 28th 35th 45th day	—

Secondary

Measure	Time frame
1) To study the disease Vicharchika and Eczema . 2) To see the effect of Pama-Dadru-Vicharchikahar lepa (1) in signs and symptoms of vicharchika i.e 1)Kandu 2)Shyava varna 3)Pidika 4)Bahu strava 5)Ruja 6)Rajyo 7)Rukshata 8) Lohit varna 3) To see the effect of Mometasone Furoate 0.1% ointment in Vicharchika .Timepoint: 7th 14th 21th 28th 35th 45th day	—

Countries

India

Contacts

Public ContactDr Suryaparakash Jaiswal

DMM Ayurved College Yavatmal

dr.skjaiswal01@gmail.com9822126706

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 12, 2026